PT  - JOURNAL ARTICLE
AU  - MICHAL KIELBUS
AU  - RADOSLAW ROLA
AU  - BOZENA JAROSZ
AU  - WITOLD JELENIEWICZ
AU  - MAREK CYBULSKI
AU  - AGNIESZKA STENZEL-BEMBENEK
AU  - ARKADIUSZ PODKOWINSKI
AU  - JOLANTA SMOK-KALWAT
AU  - KRZYSZTOF POLBERG
AU  - TOMASZ TROJANOWSKI
AU  - DAWID STEFANIUK
AU  - ANDRZEJ STEPULAK
TI  - Epidermal Growth Factor Receptor and its Oncogenic <em>EGFRvIII</em> Variant in Benign and Malignant Brain Tumors
AID  - 10.21873/anticanres.14852
DP  - 2021 Feb 01
TA  - Anticancer Research
PG  - 983--991
VI  - 41
IP  - 2
4099  - http://ar.iiarjournals.org/content/41/2/983.short
4100  - http://ar.iiarjournals.org/content/41/2/983.full
SO  - Anticancer Res2021 Feb 01; 41
AB  - Background/Aim: Tumorigenesis and cancer progression might be driven by abnormal activation of growth factor receptors. Importantly, molecular changes in EGFR-dependent signaling is one of the most common characteristics of brain tumors. Patients and Methods: HER1 and EGFRvIII variants in meningiomas and glioblastomas were evaluated at the RNA level. Results: EGFRvIII was found in 18.6% of glioblastomas (GBM), whereas 25% of EGFRvIII positive tumors express wild-type EGFR as well. HER1 was over-expressed in benign meningiomas compared to glioblastomas, whereas HER1 expression in meningiomas differed significantly between sub-types of meningiomas. EGFRvIII and HER1 where positively correlated in glioblastomas. Yet, the patient overall survival did not differ between high- and low-HER1 expressing glioblastomas or between EGFRvIII positive and negative GBMs. Conclusion: HER1 may be considered as an independent factor for classification of benign meningiomas. The mRNA levels of HER1 or EGFRvIII should not be used as independent prognostic factors for patients with gliomas.